TransCode Therapeutics Statistics

Total Valuation

RNAZ has a market cap or net worth of $8.89 million. The enterprise value is $5.76 million.

Market Cap	8.89M
Enterprise Value	5.76M

Important Dates

The next estimated earnings date is Tuesday, November 12, 2024, after market close.

Earnings Date	Nov 12, 2024
Ex-Dividend Date	n/a

Share Statistics

RNAZ has 17.27 million shares outstanding. The number of shares has increased by 15,673.51% in one year.

Shares Outstanding	17.27M
Shares Change (YoY)	+15,673.51%
Shares Change (QoQ)	+37.12%
Owned by Insiders (%)	0.04%
Owned by Institutions (%)	11.64%
Float	17.26M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	2.83
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.25, with a Debt / Equity ratio of 0.17.

Current Ratio	1.25
Quick Ratio	0.96
Debt / Equity	0.17
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-364.86

Financial Efficiency

Return on equity (ROE) is -1,048.70% and return on invested capital (ROIC) is -611.30%.

Return on Equity (ROE)	-1,048.70%
Return on Assets (ROA)	-207.95%
Return on Capital (ROIC)	-611.30%
Revenue Per Employee	n/a
Profits Per Employee	-$1.79M
Employee Count	10
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -96.37% in the last 52 weeks. The beta is 0.65, so RNAZ's price volatility has been lower than the market average.

Beta (5Y)	0.65
52-Week Price Change	-96.37%
50-Day Moving Average	0.47
200-Day Moving Average	0.68
Relative Strength Index (RSI)	46.76
Average Volume (20 Days)	1,334,605

Short Selling Information

The latest short interest is 1.22 million, so 7.07% of the outstanding shares have been sold short.

Short Interest	1.22M
Short Previous Month	1.38M
Short % of Shares Out	7.07%
Short % of Float	7.07%
Short Ratio (days to cover)	0.38

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-17.81M
Pretax Income	-17.06M
Net Income	-17.91M
EBITDA	-17.68M
EBIT	-17.81M
Earnings Per Share (EPS)	-$5.57

Full Income Statement

Balance Sheet

The company has $3.35 million in cash and $227,246 in debt, giving a net cash position of $3.13 million or $0.18 per share.

Cash & Cash Equivalents	3.35M
Total Debt	227,246
Net Cash	3.13M
Net Cash Per Share	$0.18
Equity (Book Value)	1.32M
Book Value Per Share	0.18
Working Capital	884,107

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$15.45 million and capital expenditures -$12,997, giving a free cash flow of -$15.46 million.

Operating Cash Flow	-15.45M
Capital Expenditures	-12,997
Free Cash Flow	-15.46M
FCF Per Share	-$0.90

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

RNAZ does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-15,673.51%
Shareholder Yield	-15,673.51%
Earnings Yield	-201.37%
FCF Yield	-173.86%

Analyst Forecast

The average price target for RNAZ is $3.00, which is 482.52% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$3.00
Price Target Difference	482.52%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-31.25%

Stock Forecasts

Stock Splits

The last stock split was on January 16, 2024. It was a reverse split with a ratio of 0.025:1.

Last Split Date	Jan 16, 2024
Split Type	Reverse
Split Ratio	0.025:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	1